FL-SINTAVIA-LLC
17.3.2021 13:01:05 CET | Business Wire | Press release
Sintavia, LLC , a designer and 3D printer of a new generation of flight and launch components, announced today that it had published an overview of proper handling procedures for powder condensate waste generated as part of the powder bed fusion additive manufacturing process. The paper, titled, “Overview of Disposal Procedures for Powder Condensate” was written by Sintavia’s Quality & EHS Engineer, Ashley Wallace, in collaboration with the Additive Manufacturer Green Trade Association (AMGTA) and Triumvirate Environmental .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005082/en/
Powder condensate is the term used to describe solidified particles resulting from the evaporation of metal alloys during the powder bed fusion additive manufacturing (AM) process. This condensate, which is a waste stream unique to AM, is either deposited into a collection chamber within the AM printer (considered to be “dry” condensate) or wet-vacuumed out of the build chamber itself (considered, along with melt spatter contemporaneously removed, to be “wet” condensate). Both wet and dry condensate may be hazardous and must be disposed of pursuant to applicable environmental regulations. As metal AM is only now entering maturity with respect to production, powder condensate as a waste stream has previously neither been a major concern for operators nor studied widely. However, high volume manufacturers increasingly need to allocate proper resources for the safe disposal of this material. In order to do so, powder condensate should be classified as a separate waste stream and documented appropriately with cost-effective methods for its disposal. This paper discusses the procedures used in the United States for analyzing and disposing of condensate from the powder bed fusion process, and provides a real world example of how one high-volume manufacturer handles this disposal
According to its author, “knowing where each condensate stream is going is just as important as the proper preparation of each type of waste. As Sintavia has grown, we have recognized that proper disposal of all of our waste streams must be a priority. We have worked with Triumvirate Environmental and other experts within the industry to manage the final disposal of these streams according to regulatory requirements.” The full paper is available to AMGTA member companies, other industry stakeholders, and the general public on the AMGTA website at: https://www.amgta.org/resources/ .
“We were pleased to work with the Additive Manufacturer Green Trade Association and Triumvirate Environmental on this paper,” said Brian Neff, Sintavia’s Chief Executive Officer. “By sharing what we’ve learned with other industry stakeholders, we hope these published guidelines can help other powder bed fusion AM manufacturers as they develop their own process to determine the safe and proper handling and disposal of powder condensate.”
About Sintavia
Sintavia designs and 3D prints a new generation of flight and launch products for the Aerospace, Defense, & Space industry. The company's ability to design and serially produce thermally engineered components with complex structural walls of less than 150 microns has unlocked a level of performance impossible to achieve using traditional manufacturing methods. With 30 high-speed printers co-located alongside precision post processing equipment, a full complement of mechanical testing equipment, and a full metallurgical and powder laboratory, Sintavia is able to optimize parameters, serially manufacture, and audit quality parts for aerospace applications. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry and holds multiple Nadcap and other aerospace accreditations. For more information, visit https://sintavia.com/ .
About AMGTA
The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process. Founding Members of the AMGTA include ExOne , Sintavia, LLC , Taiyo Nippon Sanso Corporation and QC Laboratories, Inc. Participating Members of the AMGTA include AMEXCI AB , BASF 3D Printing Solutions , Danish AM Hub , DyeMansion , EOS , Fraunhofer Institute for Laser Technology (ILT) , GE Additive , HP, Inc. , Materialise , National Manufacturing Institute Scotland , Rusal America , Siemens Digital Industries Software , SLM Solutions Inc. , Stryker , The Barnes Global Advisors , TRUMPF , and 6K . For more information, please contact Sherry Handel, at +1 954.308.0888, or visit www.amgta.org .
About Triumvirate Environmental
Triumvirate Environmental is a leading provider of enterprise waste management and environmental services to Healthcare, Education, Life Sciences and Industrial markets. It prides itself on its attention to safety, sustainability, and innovative solutions. Service offerings include environmental waste reduction, waste management plan creation and implementation, and green and sustainable solution development. Learn more at www.triumvirate.com or call us at 888-834-9697.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
